TY  - JOUR
A1  - Shityakov, Sergey
A1  - Nagai, Michiaki
A1  - Ergün, Süleyman
A1  - Braunger, Barbara M.
A1  - Förster, Carola Y.
T1  - The protective effects of neurotrophins and microRNA in diabetic retinopathy, nephropathy and heart failure via regulating endothelial function
JF  - Biomolecules
N2  - Diabetes mellitus is a common disease affecting more than 537 million adults worldwide. The microvascular complications that occur during the course of the disease are widespread and affect a variety of organ systems in the body. Diabetic retinopathy is one of the most common long-term complications, which include, amongst others, endothelial dysfunction, and thus, alterations in the blood-retinal barrier (BRB). This particularly restrictive physiological barrier is important for maintaining the neuroretina as a privileged site in the body by controlling the inflow and outflow of fluid, nutrients, metabolic end products, ions, and proteins. In addition, people with diabetic retinopathy (DR) have been shown to be at increased risk for systemic vascular complications, including subclinical and clinical stroke, coronary heart disease, heart failure, and nephropathy. DR is, therefore, considered an independent predictor of heart failure. In the present review, the effects of diabetes on the retina, heart, and kidneys are described. In addition, a putative common microRNA signature in diabetic retinopathy, nephropathy, and heart failure is discussed, which may be used in the future as a biomarker to better monitor disease progression. Finally, the use of miRNA, targeted neurotrophin delivery, and nanoparticles as novel therapeutic strategies is highlighted.
KW  - diabetic retinopathy
KW  - diabetes mellitus
KW  - microvascular complications
KW  - diabetic nephropathy
KW  - heart failure
KW  - microRNA
KW  - neurotrophins
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-285966
SN  - 2218-273X
VL  - 12
IS  - 8
ER  - 
TY  - JOUR
A1  - Reschke, Moritz
A1  - Salvador, Ellaine
A1  - Schlegel, Nicolas
A1  - Burek, Malgorzata
A1  - Karnati, Srikanth
A1  - Wunder, Christian
A1  - Förster, Carola Y.
T1  - Isosteviol sodium (STVNA) reduces pro-inflammatory cytokine IL-6 and GM-CSF in an in vitro murine stroke model of the blood–brain barrier (BBB)
JF  - Pharmaceutics
N2  - Early treatment with glucocorticoids could help reduce both cytotoxic and vasogenic edema, leading to improved clinical outcome after stroke. In our previous study, isosteviol sodium (STVNA) demonstrated neuroprotective effects in an in vitro stroke model, which utilizes oxygen-glucose deprivation (OGD). Herein, we tested the hypothesis that STVNA can activate glucocorticoid receptor (GR) transcriptional activity in brain microvascular endothelial cells (BMECs) as previously published for T cells. STVNA exhibited no effects on transcriptional activation of the glucocorticoid receptor, contrary to previous reports in Jurkat cells. However, similar to dexamethasone, STVNA inhibited inflammatory marker IL-6 as well as granulocyte-macrophage colony-stimulating factor (GM-CSF) secretion. Based on these results, STVNA proves to be beneficial as a possible prevention and treatment modality for brain ischemia-reperfusion injury-induced blood–brain barrier (BBB) dysfunction.
KW  - IL-6
KW  - ischemia
KW  - isosteviol sodium (STVNA)
KW  - dexamethasone
KW  - glucocorticoid receptor
KW  - cerebEND
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-286275
SN  - 1999-4923
VL  - 14
IS  - 9
ER  -